vadimezan has been researched along with evans blue in 1 studies
| Studies (vadimezan) | Trials (vadimezan) | Recent Studies (post-2010) (vadimezan) | Studies (evans blue) | Trials (evans blue) | Recent Studies (post-2010) (evans blue) |
|---|---|---|---|---|---|
| 272 | 16 | 101 | 2,119 | 12 | 405 |
| Protein | Taxonomy | vadimezan (IC50) | evans blue (IC50) |
|---|---|---|---|
| Luciferin 4-monooxygenase | Photinus pyralis (common eastern firefly) | 5.4 | |
| 60 kDa heat shock protein, mitochondrial | Homo sapiens (human) | 0.17 | |
| Tyrosine-protein phosphatase non-receptor type 1 | Homo sapiens (human) | 1.3 | |
| Tyrosine-protein phosphatase 1 | Saccharomyces cerevisiae S288C | 1.2 | |
| 10 kDa heat shock protein, mitochondrial | Homo sapiens (human) | 0.17 | |
| Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 | Homo sapiens (human) | 0.922 | |
| Thiosulfate sulfurtransferase | Homo sapiens (human) | 8.7 | |
| 60 kDa chaperonin | Escherichia coli | 0.063 | |
| 10 kDa chaperonin | Escherichia coli | 0.063 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baguley, BC; Ching, LM; Chung, F; Liu, J | 1 |
1 other study(ies) available for vadimezan and evans blue
| Article | Year |
|---|---|
Consequences of increased vascular permeability induced by treatment of mice with 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and thalidomide.
Topics: Animals; Antineoplastic Agents; Body Temperature; Capillary Permeability; Colonic Neoplasms; Coloring Agents; Drug Synergism; Evans Blue; Hematocrit; Liver Circulation; Mice; Mice, Inbred C57BL; Thalidomide; Xanthones | 2008 |